|
The XIth meeting of the European Society for Immunology (ESID) together with the VIIIth meeting of the International Patient Organisation of Primary Immunodeficiencies (IPOPI) and the VIth meeting of the International Nursing Group for Immunodeficiencies (INGID) will be held in Versailles from October 21 to 24, 2004. |
|
|
Read more...
|
|
Oct. 25, 2004
The revised American Heart Association (AHA) guidelines on Kawasaki disease, published in the Oct. 26, 2004, issue of Circulation, provide recommendations to guide the clinician in deciding which children to treat for Kawasaki disease. This statement is also endorsed by the American Academy of Pediatrics and copublished in the upcoming Dec. 1, 2004, issue of Pediatrics. |
|
Read more...
|
Press release
Cooperation on medicines regulation intensified
The EU-FDA confidentiality arrangement was reviewed at a meeting in Brussels on 13 March 2006 of
the European Commission, the European Medicines Agency (EMEA) and the US Food and Drug
Administration (FDA). The implementation plan for the arrangement was judged by all parties to have been a success.
Following positive feedback from both regulators and industry that parallel scientific advice can
facilitate the development of safe and effective medicines, it was agreed to extend the pilot phase for this process. Another area of particular benefit is pharmacovigilance, where close collaboration on a number of important issues has enhanced patient safety.
|
|
Read more...
|
|
 | The new ebsite of ESID hes been released. The url has not changed www.esid.org. The new website is easy to navigate and visitors can get access to information on the documenting centers of the ESID online registry. Some other data is published on the website, total number of patients included in the registry database(s) and number of diagnoses from the different countries.
click here to go to the website
|
|
|
High-dose intravenous immunoglobulin pulse therapy
in patients with progressive immunoglobulin A nephropathy: a long-term
follow-up.
Clin Exp Immunol. 2006 Oct;146(1):47-53.
Rasche FM, Keller F, Lepper PM, Aymanns C, Karges W, Sailer LC, Muller L, Czock D.
Division of Nephrology, Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
In
progressive immunoglobulin A nephropathy (IgAN), intravenous
immunoglobulin (IVIg) treatment has been used to delay disease
progression, but the long-term efficacy is largely unknown. We report
the clinical outcomes after IVIg therapy in six male patients with
progressive IgAN [median glomerular filtration rate (GFR) 31 ml/min per
1.73 m(2)] followed for a median observation period of 8 years.
|
|
Read more...
|
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 1 of 36 |
